InSphero Organ-on-a-Chip Solutions Featured in SLAS Technology
Early proof-of-concept studies demonstrate the versatility of scalable microfluidic platforms for 3D microtissue-based multi-organ models.
Schlieren, Switzerland – January 31, 2019 – The February 2019 issue of the scientific journal SLAS Technology showcases the innovative, scalable microfluidic platform that inspired InSphero’s new organ-on-a-chip system: Akura™ Flow. InSphero Head of Technology and Platforms Dr. Olivier Frey and co-authors from Prof. Andreas Hierlemann’s bioengineering lab at ETH Zürich were invited to contribute the article for the journal as top finalists for the prestigious SLAS Innovation Award in 2018.
InSphero has been testing and perfecting organ-on-a-chip solutions since 2011, when the company teamed up with ETH, AstraZeneca, and other leading academic groups in the EU-supported research project, Body-on-a-Chip, that aimed to mimic the response of the human body as a whole to drugs for safety and efficacy testing. Working in collaboration, microfluidics experts at ETH Zürich and InSphero were able to refine early prototypes of the system and create the basis for a higher-order system suitable for applications such as low clearance assays and metabolic disease modeling.
Since then, InSphero has been working on commercializing the Akura™ Flow system to ensure the operational robustness and trustworthy results demanded by the pharmaceutical industry. Akura™ Flow is also the first technology to address important industry needs, such as short setup times of one week and the capability to automatically extract 3D microtissues from the device for downstream next-gen sequencing, histology, or other rich endpoints.
Dr. Frey, who spearheads Akura™ Flow product development, says, “This is truly an exciting time to be working in the field of biomedical microfluidics. In partnership with our customers, we can now develop a wide range of multi-tissue configurations, from tumor-liver-immune system interactions for cancer research to liver-pancreatic islet communications for the study of metabolic diseases, such as diabetes and NASH. Our technology provides researchers with a completely new tool for studying complex diseases and discovering new cures.”
InSphero will present on Akura™ Flow and 3D human tissue models for drug discovery and development at SLAS2019, Feb 2-6, in Washington, DC. The company will also participate in the SLAS Exhibition and can be found at booth 848.
To read more about the SLAS Technology paper, please visit “Scalable Microfluidic Platform for Flexible Configuration of and Experiments with Microtissue Multiorgan Models.”
